Tumor heterogeneity is a major hurdle for cancer treatment success. To effectively enroll patients in clinical trials, the identification of predictive biomarkers at the preclinical stage is crucial. The use of patient-derived xenograft (PDX) tumor models facilitates the identification of biomarkers that predict the tumor’s response to therapy. In addition, the assessment of PDX models on broad screening platforms such as 3D culture and in vivo mouse clinical trials (humanized and immunodeficient) accelerates compound evaluation.

This webinar discusses the use of PDX models in preclinical drug development and the benefits of using this approach on clinical trial outcomes. Click below to view the slides of the presentation.


  • Vincent Vuaroqueaux, PhD, Dept. Head of Biomarker Development & Bioinformatics, Oncotest, Freiburg, Germany